Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026
Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Fineline Cube Feb 10, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Fineline Cube Feb 10, 2026
Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma

Fineline Cube Feb 21, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co.,...

Company Drug

GSK’s Nucala Receives NMPA Review for COPD Treatment

Fineline Cube Feb 21, 2025

GSK plc (LON: GSK, NYSE: GSK) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Nuwacell Biotech’s NCR101 Approved for ILD Clinical Study by China’s CDE

Fineline Cube Feb 21, 2025

According to the Center for Drug Evaluation (CDE) website, China-based Nuwacell Biotechnology Co., Ltd. has...

Company

Baxter International Reports Q4 2024 Revenues of USD 2.75B, Up 2% YOY

Fineline Cube Feb 21, 2025

Baxter International (NYSE: BAX) announced its fourth-quarter 2024 financial results, reporting revenues of USD 2.75...

Company Deals Medical Device

Horimed Raises USD 13.8M to Advance Optical and Ultrasonic Imaging Tech

Fineline Cube Feb 21, 2025

Horimed, a Tianjin-based medical device firm specializing in optical and ultrasonic medical imaging technology and...

Company Deals

Gene Cradle and Byongen Therapeutics Partner on Next-Generation DMD Gene Therapies

Fineline Cube Feb 21, 2025

Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance...

Company Drug

Bristol-Myers Squibb’s Opdivo Shows Survival Benefit in CheckMate-816 Study

Fineline Cube Feb 21, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from...

Company Drug

Corxel Pharmaceuticals to Test JX10 in Acute Ischemic Stroke Patients with NMPA Approval

Fineline Cube Feb 21, 2025

China-based Corxel Pharmaceuticals (CORXEL) has received approval from the National Medical Products Administration (NMPA) to...

Company Deals

Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development

Fineline Cube Feb 21, 2025

China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...

Company Drug

Gilead’s Livdelzi Receives Conditional EC Approval for Primary Biliary Cholangitis

Fineline Cube Feb 21, 2025

US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that it has received conditional approval from the...

Company Deals

FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included

Fineline Cube Feb 21, 2025

US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China...

Company Deals

Waterdrop Integrates DeepSeek AI to Boost Insurance Ecosystem

Fineline Cube Feb 21, 2025

China-based Waterdrop Inc. (NYSE: WDH), a crowdfunding-based health insurance platform, announced a strategic integration with...

Company Drug

Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931

Fineline Cube Feb 21, 2025

German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for...

Company Drug

Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review

Fineline Cube Feb 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...

Policy / Regulatory

Stabilizing Foreign Investment: China’s Comprehensive Action Plan for 2025

Fineline Cube Feb 20, 2025

In a significant move to bolster foreign investment and enhance the country’s economic openness, the...

Company Deals

Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research

Fineline Cube Feb 20, 2025

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Drug

Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China

Fineline Cube Feb 20, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, announced the...

Company Drug

Bayer’s AskBio Receives RMAT Designation for AB-1005 in Parkinson’s Disease

Fineline Cube Feb 20, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that its gene therapy subsidiary AskBio Inc. has...

Company Drug

Phanes Therapeutics Doses First Patient in Peluntamig Study for SCLC and NEC

Fineline Cube Feb 20, 2025

Sino-US biotech Phanes Therapeutics Inc. announced that the first patient has been dosed in a...

Company Deals

Epitopea and Merck Partner to Identify Cryptigen Tumor Antigens

Fineline Cube Feb 20, 2025

UK-based RNA immunotherapy developer Epitopea announced a licensing and research cooperation agreement with US pharmaceutical...

Posts pagination

1 … 165 166 167 … 622

Recent updates

  • Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million
  • Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med
  • Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage
  • Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology
  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.